Abstract:
Actuality: Corneal collagen crosslinking with riboflavin and Ultraviolet-A is a
technique of corneal tissue strengthening that combines the use of riboflavin as a
photo sensitizer and UVA irradiation. The major indication for the use of CXL is to
inhibit the progression of corneal ecstasies, such as keratoconus. Most recent
studies demonstrate the beneficial impact of CXL for iatrogenic ecstasies, pellucid
marginal degeneration, infectious keratitis, bullous keratopathy and ulcerative
keratitis.
Purpose of the study: Assessing the effectiveness of Corneal collagen crosslinking in
keratoconus and other corneal diseases.
Methods: Clinical prospective study, that included 281 eyes with moderate or
advanced progressive keratoconus (K: 48 – 72 D) and 64 eyes with other corneal
diseases: pellucid marginal degeneration, iatrogenic ecstasies, infectious keratitis,
bullous keratopathy and ulcerative keratitis. CXL epi-on is performed without
desepitalization of the cornea with balanced solution of riboflavin instilled for 20
minutes and UVA exposure (365 nm, 18mW/cm2) for 5 minutes. Postoperative
examinations were carried over the course of 1 day,1 week, 1, 3 and 6 months, 1
year, including visual acuity, biomicroscopy, corneal topography, pachymetry,
refractometry, keratometry.
Results: In all treated eyes, the progression of keratoconus and pellucid marginal
degeneration was stopped. In eyes with bullous kerathopaty corneal thickness was
reduced by 71.54±14.02 micron and visual acuity was significantly improved. In all
cases with infectios melting keratitis the progression of corneal melting was halted.
Conclusions: Application for CXL is attractive in that it offers the potential to reduce
the need for corneal transplantation in a condition other than keratoconus. It may
also offer another means of controlling pain in patients with bullous keratopathy
who are either unsuitable for or awaiting keratoplasty. The results follows that many
corneal infections may be controlled with a single treatment.
